Table 6.
Summary of Clinical Studies Assessing PK Parameters of Micafungin in Critically Ill Patients.
| Clinical Context | Dose | AUC0–24 (mg h/L) | AUC/MIC ratio | Cl (L/h) | Vd (L) | Reference |
|---|---|---|---|---|---|---|
| 1. ICU patients receiving micafungin for suspected or proven fungal infection | Standard * | 91 (67–122) | - | 1.10 | 17.6 | [86] |
| 150 mg daily | 137 (101–183) | - | ||||
| 200 mg daily | 183 (135–244) | - | ||||
| 2. ICU patients treated with micafungin for a suspected or proven invasive candida infection | Standard * | 89.6 | 6221 (C. albicans) 5643 (C. glabrata) | - | - | [95] |
| 3. ICU patients with sepsis and mechanical ventilation | Standard * | 65.5 ** | - | 1.34 L/h | 11.80 | [98] |
| 4. ICU patients treated with micafungin for a suspected or proven invasive candida infection | Standard * | 76.33 | - | 1.31 L/h | 14.2 L | [100] |
* Standard dose for micafungin: 100 mg daily ** In patients with a SOFA score < 10, and albumin levels ≤ 25 g/L.